The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets.
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth.
This growth will be driven by a rising treatment population and the continued uptake of biologics.
Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar competitors, this will be offset by the emergence of novel therapies.
Most notably, these include monoclonal antibodies secukinumab, ixekizumab and brodalumab, which are currently being developed by Alcon (Novartis subsidiary), Eli Lilly and Amgen, respectively.
Scope
- Analysis of the major systemic therapies in the current psoriasis marketed landscape
- Analysis of the pipeline for psoriasis, which includes a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided.
- Forecast projections for the systemic psoriasis market to 2020. Analysis is provided for the global market and each of the eight major markets.
The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.
- Analysis of strategic consolidations, including co-development and licensing deals, within the psoriasis indication
Key Attribute of Report
- Understand the current systemic psoriasis marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
- Identify trends and developments within the psoriasis pipeline and consider how the future competitive environment will be impacted
- Consider market opportunities and potential risks by examining the psoriasis clinical trial landscape in relation to industry averages
- Observe projections for treatment usage patterns, annual therapy costs and market growth in the eight major markets and understand reasons for variance in projected patterns of growth in the eight major markets
Table of Contents
1 Introduction
1.1 Overview
1.2 Epidemiology
1.3 Etiology, Co-morbidities and Risk Factors
1.4 Pathophysiology
1.5 Diagnosis
1.6 Treatment Options
1.7 Summary
2 Marketed Products
2.1 Overview
2.2 Methotrexate-based Products
2.3 Sandimmune/Neoral (cyclosporine/modified cyclosporine) - Novartis
2.4 Soriatane (acitretin) - Steifel Laboratories
2.5 Fumaderm (dimethyl fumarate and ethyl fumarate) - Biogen Idec
2.6 Humira (adalimumab) - Abbvie Inc.
2.7 Enbrel (etanercept) - Amgen Inc.
2.8 Remicade (infliximab) - Janssen Biotech
2.9 Stelara (ustekinumab) - Janssen Biotech
2.10 Marketed Products Heat Map
3 Pipeline
3.1 Overview
3.2 Pipeline Size and Distribution by Phase, Molecule Type and Program Type
3.3 Pipeline Distribution by Molecular Target 31
3.4 Clinical Trial Landscape
3.5 Clinical trial failure rates
3.6 Primary and Secondary Endpoints
3.7 Summary of Psoriasis Clinical Trials
3.8 Promising pipeline molecules
3.9 Heat Map for Pipeline Products
4 Market Forecast to 2020
4.1 Overview
4.2 Global Market
4.3 North America
4.4 Top Five EU Markets
4.5 Japan
4.6 Drivers and Barriers for the Systemic Psoriasis Therapeutics Market
5 Co-development and Licensing deals
5.1 Co-development Deals
5.2 Licensing Deals
6 Appendix
6.1 All Pipeline Drugs by Phase
6.2 Market Forecasts to 2020
6.3 Abbreviations
6.4 References
6.5 References for Heat Maps
6.6 Methodology 100
For more information:
News From
Big Market Research Category: Industry Reports & Market Analysis Profile: With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market ...
